About Tivic Health Systems, Inc. - Common stock (TIVC)
Tivic Health Systems, Inc. is a medical technology company focused on developing innovative solutions for chronic conditions affecting the upper respiratory tract. The company specializes in advanced neuromodulation therapies, which leverage electrical stimulation to address symptoms associated with conditions such as rhinitis and sinusitis. By utilizing its proprietary technology, Tivic Health aims to enhance patient quality of life through non-invasive treatment options that offer an alternative to traditional medication. Their commitment to research and development positions them at the forefront of transforming how patients manage their health. Read More
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, is proud to announce it advanced discussions with key US Government agencies through its participation in the 2025 Military Health System Research Symposium (MHSRS), held August 4-7, 2025, in Kissimmee, Florida. The MHSRS is the Department of Defense’s premier scientific meeting that brings together military, academic, and industry experts to discuss medical research and innovation in support of warfighter health and readiness.
Tivic Health® Systems, Inc. (NASDAQ: TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced that it will report its second quarter results for 2025 via pre-recorded conference call and webcast on Thursday, August 14, 2025 at 1:30 PM PT / 4:30 PM ET.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that key proposals needed to carry out the company’s strategic transformation were approved by shareholders at its annual meeting held on June 30, 2025.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced it has completed all study visits in the Optimization Study for its patent pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Initial findings reinforce the importance of personalization for therapeutic efficacy. Tivic expects to release the study results later this year.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today its Virtual Annual General Meeting of Shareholders will be held on Monday, June 30, 2025 at 1:00 PM, Pacific Time | 4:00 PM Eastern Time.
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Conference taking place Wednesday and Thursday, May 21-22, 2025. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2025 and outlined operational highlights based on its newly expanded clinical pipeline.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food & Drug Administration.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today it is expanding its non-invasive VNS patent portfolio with the filing of a new patent application with the United States Patent and Trademark Office. Patent No. 63,801,058 entitled “Vagus Nerve Stimulation System” expands the claims and protection around the technology that Tivic is developing and which it expects will redefine state-of-the art in non-invasive vagus nerve stimulation.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its first quarter results for 2025 via pre-recorded conference call and webcast on Thursday, May 15, 2025 at 1:30 PM PT / 4:30 PM ET.
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
